Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Fang · SciRah

Researcher profile · Semantic Scholar

W. Fang

Share profile

W. Fang — researcher profile on SciRah

h-index: 54
Works: 338
Citations: 12K

Most-cited papers

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yun-Peng Yang, Jian-Ji Pan, Hong Wang, Yuan-Yuan Zhao +26 more
2023Cancer Cell234 citations Open access
Semantic Scholar
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
W. Fang, Yuan-Yuan Zhao, Yongzhong Luo, Run-Xiang Yang +65 more
2024Journal of the American Medical Association (JAMA)223 citations Open access
Semantic Scholar
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.
Yu-Xiang Ma, Yan Huang, Yuan-Yuan Zhao, Shen Zhao +21 more
2024The Lancet Oncology132 citations
Semantic Scholar
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Yuan-Yuan Zhao, Gang Chen, Jian-Hua Chen, L. Zhuang +17 more
2023EClinicalMedicine116 citations Open access
Semantic Scholar
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
H. Long, Q. Jia, Liuyang Wang, W. Fang +22 more
2022Cancer Cell116 citations Open access
Semantic Scholar
Classification of Tumor Immune Microenvironment (TIME) According to PD-L1 Expression and Immune Infiltration Predicts Response to Immunotherapy plus Chemotherapy in Advanced NSCLC Patients.
Dongchen Sun, Jia-Qing Liu, Huaqiang Zhou, M. Shi +12 more
2023Journal of Thoracic Oncology73 citations Open access
Semantic Scholar
Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1
F. Liang, Gui-Zhen Wang, Yan Wang, Ya-Ning Yang +15 more
2022Signal Transduction and Targeted Therapy55 citations Open access
Semantic Scholar
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
Yu-Xiang Ma, Jinhui Xue, Yuan-Yuan Zhao, Yang Zhang +12 more
2023Journal for ImmunoTherapy of Cancer45 citations Open access
Semantic Scholar
STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/IFN-I/CD8+ T cell Dysfunction in Non-Small Cell Lung Cancer.
An-Lin Li, Yuanyuan Wang, Zhixin Yu, Zihui Tan +12 more
2023Journal of Thoracic Oncology41 citations Open access
Semantic Scholar
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
Yun-Peng Yang, Jie Min, N. Yang, Qi-Tao Yu +16 more
2023Signal Transduction and Targeted Therapy37 citations Open access
Semantic Scholar
A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
Jia-Yi Shen, Hua-Qiang Zhou, Jia-Qing Liu, Ya-Xiong Zhang +5 more
2021Cancer Medicine37 citations Open access
Semantic Scholar
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Cheng-Zhi Zhou, Yinyin Qin, Wei Zhao, Zhen-Yu Liang +108 more
2023Translational Lung Cancer Research36 citations Open access
Semantic Scholar
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Mengting Shi, L. Pang, Huaqiang Zhou, S. Mo +15 more
2024Lung Cancer31 citations
Semantic Scholar
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors
Chun-Wei Xu, Yong-Chang Zhang, Wen-Xian Wang, Qianqian Wang +104 more
2023Thoracic Cancer31 citations Open access
Semantic Scholar
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
W. Fang, Ying Cheng, Zhen-Dong Chen, Wen Wang +16 more
2023Journal of Clinical Oncology28 citations
Semantic Scholar
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Li Zhang, Yu-Xiang Ma, Yuan-Yuan Zhao, W. Fang +15 more
2023Journal of Clinical Oncology27 citations
Semantic Scholar
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study
Yan Huang, Yun-Peng Yang, Yuan-Yuan Zhao, Hong-Yun Zhao +11 more
2024Signal Transduction and Targeted Therapy26 citations Open access
Semantic Scholar
RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.
Li Zhang, Yun-Peng Yang, Jian-Ji Pan, Xiao-Zhong Chen +14 more
2022Journal of Clinical Oncology25 citations
Semantic Scholar
FOXM1 variant contributes to gefitinib resistance via activating wnt/β-catenin signal pathway in non-small cell lung cancer patients.
S. Guan, Xi Chen, Youhao Chen, Wen Xie +11 more
2022Clinical Cancer Research25 citations
Semantic Scholar
Exploration of immunotherapy in advanced pulmonary lymphoepithelioma‐like carcinoma
Lanlan Pang, J. Liao, Yihua Huang, Jiadi Gan +5 more
2023International Journal of Cancer24 citations
Semantic Scholar
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
Qian Wang, Chunwei Xu, Wen-Xian Wang, Yong-Chang Zhang +107 more
2023Thoracic Cancer22 citations Open access
Semantic Scholar
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
Shen Zhao, W. Zhuang, Bao-Hui Han, Zheng-Bo Song +23 more
2023Nature Communications21 citations Open access
Semantic Scholar
Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients
Chao Fang, W. Fang, Liqin Xu, Fangfang Gao +18 more
2022Frontiers in Oncology21 citations Open access
Semantic Scholar
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768I
Lanlan Pang, Jiadi Gan, Jiarong Tan, Yihua Huang +4 more
2022Cancer21 citations
Semantic Scholar
Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study
W. Fang, Ying Cheng, Zhen-Dong Chen, Wei Wang +16 more
2024Cancer Research20 citations
Semantic Scholar
TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits
Yixuan Wang, Jia-Yin Wang, W. Fang, Xiao-e Xiao +7 more
2023Frontiers in Immunology20 citations Open access
Semantic Scholar
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Wen-Xian Wang, Qian Wang, Chun-Wei Xu, Zi-Ming Li +76 more
2022Thoracic Cancer20 citations Open access
Semantic Scholar
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
Yuan-Yuan Zhao, Li Zhang, W. Fang, Yun-Peng Yang +10 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma
Yu-Xiang Ma, Huaqiang Zhou, F. Luo, Yang Zhang +11 more
2024npj Precision Oncology18 citations Open access
Semantic Scholar
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
Yu-Xiang Ma, Hui Pan, Yu Liu, Yang Zhang +12 more
2022Journal of Thoracic Disease18 citations Open access
Semantic Scholar
Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
Shi-Rong Zhang, Wen-Xian Wang, Chun-Wei Xu, Yong-Chang Zhang +95 more
2022Thoracic Cancer17 citations Open access
Semantic Scholar
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors
Chun-Wei Xu, Qian Wang, Dong Wang, Wen-Xian Wang +117 more
2024Global Medical Genetics16 citations Open access
Semantic Scholar
Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
Liqin Xu, Yu-Xiang Ma, Chao-ping Fang, Zhuobing Peng +9 more
2022Frontiers in Oncology16 citations Open access
Semantic Scholar
TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds
Yixuan Wang, Xin Lai, Jia-Yin Wang, Ying Xu +6 more
2022Frontiers in Immunology16 citations Open access
Semantic Scholar
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Yuan-Yuan Zhao, W. Fang, Yun-Peng Yang, Jian-Hua Chen +16 more
2022Journal of Clinical Oncology16 citations
Semantic Scholar
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
Chun-Wei Xu, L. Si, Wen-Xian Wang, Zi-Ming Li +107 more
2022Thoracic Cancer15 citations Open access
Semantic Scholar
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
J. Duan, W. Fang, Hairong Xu, Jin-Liang Wang +31 more
2023Journal of the National Cancer Center14 citations Open access
Semantic Scholar
LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
Dongcheng Liu, Hongguang Liu, Jiadi Gan, Shi-Nuan Zeng +10 more
2022Frontiers in Pharmacology13 citations Open access
Semantic Scholar
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
Yu-Xiang Ma, Fu-rong Liu, Yang Zhang, Qun Chen +12 more
2022Frontiers in Immunology13 citations Open access
Semantic Scholar
Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
Yang Wei, Benyuan Jiang, Shulin Liu, Zhonghan Zhang +5 more
2021JTO Clinical and Research Reports13 citations Open access
Semantic Scholar
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma
Yu-Xiang Ma, F. Luo, Yang Zhang, Qian-Wen Liu +14 more
2024Cell Reports Medicine12 citations Open access
Semantic Scholar
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Lanlan Pang, Jiadi Gan, Yihua Huang, J. Liao +5 more
2023BMC Cancer12 citations Open access
Semantic Scholar
A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold
Yixuan Wang, Xin Lai, Jia-Yin Wang, Ying Xu +6 more
2022Frontiers in Genetics11 citations Open access
Semantic Scholar
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
Yu-Xiang Ma, Hong-Yun Zhao, Jinhui Xue, Li Liu +21 more
2022European Journal of Cancer11 citations
Semantic Scholar
FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
S. Guan, Xi Chen, Youhao Chen, Guohui Wan +14 more
2022Acta Pharmaceutica Sinica B11 citations Open access
Semantic Scholar
Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
Si-Chong Han, Gui-Zhen Wang, Ya-Ning Yang, W. Fang +6 more
2023Signal Transduction and Targeted Therapy10 citations Open access
Semantic Scholar
Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenes
Lanlan Pang, W-T. Zhuang, Yihua Huang, J. Liao +4 more
2024Journal of the National Cancer Center9 citations
Semantic Scholar
Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China
X. Pu, Chunwei Xu, Qianqian Wang, Wen-Xian Wang +99 more
2023Thoracic Cancer9 citations Open access
Semantic Scholar
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
Yi-Xing Wang, Sha Fu, Xuan-Ye Zhang, Wei Du +10 more
2023Frontiers in Immunology9 citations Open access
Semantic Scholar
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
Li Zhang, W. Fang, Yuan-Yuan Zhao, Yun-Peng Yang +15 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Yun-Peng Yang×24
Invite
Yun-Peng Yang — researcher profile on SciRah
Yan Huang×20
Invite
Yan Huang — researcher profile on SciRah
Li Zhang×14
Invite
Li Zhang — researcher profile on SciRah
Yuan-Yuan Zhao×12
Invite
Yuan-Yuan Zhao — researcher profile on SciRah

×11

Invite

Hong-Yun Zhao — researcher profile on SciRah

Yu-Xiang Ma×10

Invite

Yu-Xiang Ma — researcher profile on SciRah

Invite

N. Yang — researcher profile on SciRah

Invite

Li Zhang — researcher profile on SciRah

Ying-Ying Du×8

Invite

Ying-Ying Du — researcher profile on SciRah

Xin-Qing Lin×8

Invite

Xin-Qing Lin — researcher profile on SciRah

Yong-Chang Zhang×8

Invite

Yong-Chang Zhang — researcher profile on SciRah

Chuan-Hao Tang×8

Invite

Chuan-Hao Tang — researcher profile on SciRah